Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for the treatment of ischemic (lack of blood flow) disease and several other diseases including cardiomyopathy (heart tissue disease) and neuropathy (nerve cell disease). Hemostemix’s initial goal is to treat heart attack (ischemic heart disease) and various ischemic conditions such as ischemic limb disease.

Hemostemix’s Product Platform (targets to repair) – ACP-01 (blood vessel cells), NCP-01 (nerve cells), CCP-01 (heart cells)

Source: Hemostemix company presentation

Hemostemix’s leading product is called ACP-01. It refers to Hemostemix’s first stem cell treatment called angiogenic cell precursor (“ACP”) one (“01”). The ACP technology uses a patient’s own stem cells to treat that patient’s disease by extracting the stem cells, growing the number of cells within 7 days, then using them to treat the patient with their own harvested stem cells. According to Hemostemix: “ACP-01 has been used as a treatment of 500 subjects, studied in including clinical trials, and are demonstrated to be completely safe and effective as a treatment of Angina, Dilated and Ischemic Cardiomyopathy, Peripheral Arterial Disease and Critical Limb Ischemia.”

Hemostemix plans to increase production of their ACP stem cell therapy for ischaemic disease

In some recent news announced in January this year, Hemostemix has ramped up their team in order to increase the production of ACP-01. Hemostemix President and CEO, Thomas Smeenk, stated: “Adding four employees to our team enables Hemostemix to produce up to 20 ACP treatments per month for clinical trials and compassionate treatments approved by regulators……We expect up to 174 revenue production slots for the first full year of production. To fill them and balance our production schedule, we are working on a forward sales plan.“

A “sales plan” suggests that the commercialization of ACP is potentially in the near term.

In a recent InvestorIntel CEO video, Thomas Smeenk revealed more about Hemostemix’s master plan. He said Hemostemix’s goal is to scale up production of ACP to “4,000 or more batches per month” and “the numbers are very significant, at $25,000 per treatment…$30,000 per treatment…..the numbers get very large very fast”.

Hemostemix’s scalable production plans over a 60-month period

Hemostemix’s sales target is to reach $360 million of risk-adjusted sales in 2027 (see below or page 14). Quite impressive given Hemostemix’s current market cap is C$16 million.

Hemostemix’s sales target is to reach $360 million of risk-adjusted sales in 2027

Source: Hemostemix company presentation

Is Hemostemix’s stem cell therapy effective?

Hemostemix’s ACP treatments have been successful to date. For example, in a 2019 Phase II CLI Trial with 12 randomized double-blind subjects, the results included: “Healing of ulcers and resolution of ischemic rest pain occurred in 10 of the 12 patients (83%). There were no clinically significant safety issues. Outcomes were maintained for up to 4.5 years……“

You can see more results including pictures in a past InvestorIntel article here.

Closing remarks

Some risks apply and there is still work ahead for Hemostemix to implement its plan of action. At this stage, the Company has received US FDA Clinical Trial approval and further regulatory approvals may be necessary, as well as further funding to achieve the Company’s goals.

The best companies develop effective products that both help society and fill a strong need. Tesla (NASDAQ: TSLA) is doing this with electric vehicles (EVs) and sustainable energy. Hemostemix is working towards becoming a leading biotech health company using stem cells to significantly help some of society’s most common and severe diseases. They have already won the World Economic Forum Technology Pioneer Award, have proven their treatment efficacy in clinical trials, and have a highly qualified management team and reputable advisors.

2023 could potentially be a breakout year for Hemostemix Inc.

In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk talks about Hemostemix achieving a major milestone this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market’s immediate positive reaction.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward with its promising therapies.

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To learn more about Hemostemix Inc., click here.

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood flow) and tissue damage, and potentially improve the quality of life? It would be hard to put a price on such a company if they could successfully commercialize or license their product or technology.

Today’s company, Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VFO), is having remarkable success, yet due to its early stage has a market cap of only C$19 million. That company is developing methods that use our own bodies’ stem cells to heal certain diseases. The key diseases of focus for now are those revolving around ischemia, such as heart disease, stroke, and diabetic vascular disease and its complications such as limb loss. Over the next year, there will also be a lot of work done on nerve cell regeneration.

Hemostemix Inc. is developing ‘stem cell therapy’ for the treatment of ischemic disease and several other diseases. Hemostemix owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

Results to date have been outstanding, as shown in the image below.

Hemostemix summary of the business and ACP-01

ACP-01 is Hemostemix’s pioneering first stem cell treatment called angiogenic cell precursor (“ACP”).  Hemostemix states: “ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.”

Note: Bold emphasis by the author.

With such stunning success, it is little wonder that Hemostemix is very keen to protect their intellectual property.

On February 14, 2022 Hemostemix announced that they had “been granted International Trademark Registration No. 1624069 for Your Fountain of Youth, a registration that is valid for a period of 10 years.”  Hemostemix further announced on March 23, 2022 that it had resolved outstanding  litigation with a settlement agreement that requires the other parties to return all data and intellectual property in relation to ACP-01 in their possession to Hemostemix.

This is a great outcome for Hemostemix and good news to investors, as the Company believes their ACP-01 intellectual property is incredibly valuable.

Hemostemix has previously published numerous other studies proving the benefit of ACP-01, notably in the treatment of ischemia in various parts of the body. Some examples include improving ischemic cardiomyopathy patients and limb ischemia patients.

Note: NCP stands for Nerve Cell Precursor. CCP stands for Cardiac Cell Precursor. These are cultivated from the patient’s own stem cells using Hemostemix’s patented technologies.

What’s next for Hemostemix?

Apart from further studies, Hemostemix is now looking towards automating production, partnering and commercialization. The goal of improving stem cell production will help lower costs and potentially expand the business. Hemostemix also intends to advance their business development plans including possible licensing of their technology.

To help fund the above, Hemostemix recently announced a $2,750,000 Convertible Debenture offering.

Closing remarks

Hemostemix’s longer-term goal is to support a higher quality of life for all of us, a veritable “fountain of youth”, where we could boost our health yearly with our own stem cells to help repair our bodies.

Hemostemix trades on a market cap of C$19 million. Risk remains high due to the early stage, however there is truly blue sky potential if the Company can successfully license or commercialize their products in future years.

Every year modern medicine makes new breakthroughs that continue to amaze. Today’s company has a breakthrough ‘stem cell therapy,’ designed to regenerate diseased and damaged tissue, focused on patient’s with “ischemic” disease (a lack of blood flow) such as limb ischemia or ischemic heart disease (often leading to a heart attack). The company is a winner of the World Economic Forum Technology Pioneer Award.

Ischemic diseases are a huge global problem. For example, ischemic heart disease (also called coronary disease) affects around 126 million individuals, which is approximately 1.72% of the world’s population, annually. Nine million deaths per annum are caused by ischemic heart disease globally. Limb ischemia, often caused by diabetes, smoking, or age, is another huge area in need of innovative and better treatment.

Today’s company is stem cell therapy developer, Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF). Hemostemix’s stem cell therapy platform uses the patient’s own blood to harvest the stem cells and uses them in a  treatment that helps to restore circulation (blood flow) in damaged tissues.

Hemostemix’s leading product, ACP-01, has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia (CLI) who have exhausted all other options to save their limb from amputation.

Hemostemix state on their website:

“Hemostemix’s proprietary platform technology is based on more than 10 years of clinical data demonstrating the ability of our autologous cell product to regenerate diseased and damaged tissue. Our efficient, scalable and cost-effective platform has the potential to generate therapies for a broad range of ischemic diseases. ACP-01, our lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is currently in a Phase 2 clinical trial in Canada and the United States.”

Note: Autologous refers to using the patient’s ‘own’ stem cells.

ACP-01 testing

Twelve patients with critical limb ischemia (CLI) and no interventional options were enrolled (10 male, 2 female, mean age 76 years) in an abstract trial test.

Hemostemix quote the results stating:

“Prior to treatment with ACP–01 or placebo, 3 patients had ischemic rest pain, 8 patients had ulceration, and one patient had gangrene. Post treatment, one patient with unremitting rest pain and toe gangrene required a below knee amputation, and one patient with gangrene of the first to third toes required a forefoot amputation. Healing of ulcers and resolution of ischemic rest pain occurred in the other 10 (83%) patients. There were no clinically significant safety issues. Outcomes have been maintained for up to 4.5 years (3.5 years for 2 patients, 3 years for 1 and 1 patient died after ulcer healing secondary to congestive heart failure at 6 months).”

Hemostemix latest development for their leading product ACP-01

Hemostemix is currently working on the source document verification for their Phase II clinical trials for their lead product ‘ACP-01’ for the treatment of critical limb ischemia (CLI), peripheral artery disease (PAD), angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. The document verification completion is expected to be completed by the end of 2021.

Note: Clinical trials follow a typical series from early, small-scale, Phase 1 studies to late-stage, large scale, Phase 3 studies, followed hopefully by FDA approval.

Closing remarks

Hemostemix is revolutionizing the way we treat ischemic disease by using stem cells developed from a patient’s own blood. Abstract trials on ACP-01 led to an 83% success rate and the Company is now working towards Phase II trials.

Hemostemix is working towards revolutionizing the way we treat lack of blood flow, ischemic, diseases by using its stem cell therapy and has a market cap of C$11 million,

Further learning

• Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain
• Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), about Hemostemix’s autologous stem cell therapy and why he calls the technology “the fountain of youth.”

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to say that Hemostemix’s lead product ACP-01 works by treating ischemia (lack of blood circulation) in a patient’s body. The technology has already been used to treat around 500 patients suffering from ischemia in the heart, arteries, and limb. He added that using the technology many patients were able to “save their limbs from otherwise certain amputations.” Hemostemix has 91 patents including a patent on the automation of production which enables the company to scale the business “exponentially” as over a million patients lose their limbs to amputation in North America alone. The technology is now in Phase 2 clinical trial.

To watch the full interview, click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete. 

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation.  Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken,  as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [email protected].

Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial program of its blood-derived, stem cell therapeutics product (ACP-01) at sites in the United States and Canada.

ACP-01 is being tested as a treatment for medical conditions such as Critical Limb Ischemia (CLI). CLI is a blockage in the arteries, which reduces blood flow and oxygen in the limbs, and can cause conditions such as severe pain in the feet or toes, wounds that won’t heal, and if left untreated, could result in the amputation of the affected limb.

Although ACP-01 has been used to treat over 500 patients, currently it is part of a Phase II clinical trial of its safety and efficacy in patients with advanced CLI who have exhausted all other options to save their limb from amputation.

Recently, Hemostemix announced an update on the ACP-01 clinical trial as the company believes that all follow-up visits of the enrolled trial subjects should be completed by March 31, 2021.

In the clinical trial, 65 subjects were enrolled and randomly 2/3 of the participants received ACP-01 with the other participants receiving a placebo. Once the last follow-up appointment is completed and trial data has been analyzed, the company will provide an update. We expect this information in late April or early May.

The earlier clinical trials have shown that ACP-01 is safe and effective in the treatment of CLI. The data collected will include treatment success or failure, pain, quality of life, and any adverse effects.

Signs “BREAD” Contract with Canadian Department of Foreign Affairs

In January, Hemostemix also announced it signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development.

The BREAD agreement is a Canadian government initiative to assist high-potential, biotech-focused Canadian Small and Medium Enterprises and is designed to accelerate the growth of Canadian biotechnology companies.

The Trade Commissioner Service (TCS) department, within the Department of Foreign Affairs, helps Canadian companies grow into international markets by assessing market potential, finding qualified partners, and resolving problems.

Hemostemix is working with the TCS to source qualified partners to license ACP-01 in foreign markets including the United States, Japan, and South Korea,

Hemostemix – a Platform for Stem Cell Therapies

Hemostemix’s stem cell therapy platform uses the patient’s own blood to harvest the stem cells and the treatment helps to restore circulation in damaged tissues.

Advantages with Hemostemix’s process include the use of blood, which is safer and less invasive than other methods, and since you are using the patient’s own blood, there is no immune rejection.

ACP-01 has the potential to treat other conditions such as Angina, Ischemic & Dilated Cardiomyopathy, and Peripheral Artery Disease. Currently, Hemostemix is preparing for Phase 2 trials for the treatment of Angina and is seeking joint-venture partners to fund other Phase 2 trials.

The company is also investigating the use of ACP-01 to treat patients hospitalized with COVID-19 that exhibit low oxygen levels and significant inflammation.

Hemostemix has also developed NCP-01 (Neural Cellular Precursor) from blood with the potential to treat neurological conditions such as Alzheimer’s, Amyotrophic Lateral Sclerosis (“ALS”), Parkinson’s, spinal cord injuries, and stroke-related issues. NCP-01 is currently in the R&D phase and is pre-clinical.

Fully Funded for the Year

In December 2020, Hemostemix raised $2.75 million at $0.30 per unit that comprised of a share and a warrant priced at $1.00 for a period of 12 months. Proceeds from the offering are expected to be used to pay for various corporate expenses and to fund the clinical trial costs.

In addition to the cash on hand, Hemostemix has a strong intellectual property (IP) portfolio of 91 patents.

To generate some cash flow, Hemostemix plans to ramp up the revenue side of the business by reinstating its compassionate care revenue stream in the United States.

Final Thoughts

Stem cell treatments have been used for over 30 years to treat people with cancer conditions such as leukemia and lymphoma and earlier trials of Hemotemix’s ACP-01 have shown positive effects in the treatment of CLI.

Factors that increase the risk of CLI include diabetes, high cholesterol levels, high blood pressure, obesity, or smoking. Unfortunately, most of these factors are increasing at an alarming rate. Treatment for these conditions has a billion-dollar market potential.

Currently, Hemostemix has a market cap of only C$25 million with similar-sized biotech companies focusing on CLI trading much higher.

As a company shifts from FDA Phase II to Phase III clinical trials, we expect the share price and market cap to shift higher to reflect the potential of ACP-01.

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about Hemostemix’s technology that uses patients own blood to treat ischemia in the circulatory system of the body.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas said, “We take blood from patient’s arm. We fractionate out their stem cell from that blood.” He continued, “Then we culture them and change them from a raw stem cell into an angiogenic cell precursor that is programed to address ischemia in the circulatory system of the body. It is common in diabetics, in individuals who suffer from heart disease such as angina or ischemic cardiomyopathy, in wound care.”

Thomas stated that Hemostemix has treated more than 500 patients using the technology which is now in clinical trials. He added, “The second one we patented is NCP (Neural Cellular Precursor). This is a cell that can be used to treat stroke, diseases that have nerve damage.”

To watch the full interview, click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemix’s patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. “I have come across some good technologies and put together a team that have succeeded,” Thomas commented.

Thomas also provided an update on Hemostemix’s ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient’s own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.

To watch the full interview, click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.